Answers are grounded in this paper and cite their sources.
Hemoglobin SS (Hb SS) disease is a genetic condition leading to acute and chronic complications in all organ systems. There is limited data on cancer treatment outcomes in this population. This case report presents a woman in her mid-40s with Hb SS disease and early-stage triple-negative breast cancer (TNBC), treated successfully with the Keynote 522 regimen combining chemotherapy (paclitaxel, carboplatin, doxorubicin and cyclophosphamide) and pembrolizumab. Despite potential risks, the patient tolerated therapy well with no sickle cell crises and only expected moderate side effects. This case demonstrates the feasibility of aggressive cancer treatment in patients with Hb SS disease when managed with close multidisciplinary care, though more research is needed on immunotherapy safety in this group.
No takes yet. Share an insight, caveat, or question.
Froessl et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: